华仁药业股份有限公司 章 程 二〇二五年五月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | | 第一节 股份发行 2 | | 第二节 | 股份增减和回购 3 | | | 第三节 股份转让 4 | | 第四章 | 股东和股东大会 5 | | | 第一节 股东 5 | | | 第二节 股东大会的一般规定 9 | | | 第三节 股东大会的召集 11 | | | 第四节 股东大会的提案与通知 12 | | | 第五节 股东大会的召开 14 | | | 第六节 股东大会的表决和决议 17 | | 第五章 | 董事会 22 | | | 第一节 董事 22 | | | 第二节 董事会 26 | | 第六章 | 总裁及其他高级管理人员 32 | | 第七章 | 监事会 34 | | | 第一节 监事 34 | | | 第二节 监事会 35 | | 第八章 | 党建工作 36 | | 第一节 | 党组织的机构设置 36 | | 第二节 | 公司党委 37 | | 第三节 | 公司纪委 38 | | 第九章 | 财务会计制度、利润分配和审计 ...

Group 1: Company Development Strategy - The company focuses on transforming and upgrading its development strategy, enhancing core competitiveness through quality, brand, variety, specifications, and dosage forms [1] - Continuous investment in R&D, with a total of CNY 234 million invested over the past three years, aiming to enrich the product matrix and enhance sustainable development capabilities [3] - The company has developed a comprehensive product line including 109 varieties and 223 specifications of drugs, as well as 37 Class II and 37 Class I medical devices [3] Group 2: Financial Performance and Shareholder Value - The company plans to consider share repurchase based on market conditions, financial status, and development strategy, ensuring compliance with disclosure obligations [1][5] - The management is committed to improving operational quality and investment value to enhance shareholder returns [5] - The company achieved profitability in Q1 2025, indicating a positive outlook for future development [12] Group 3: Debt Management and Risk Control - The company has established a debt resolution framework with China National Pharmaceutical Group, allowing for debt repayment through equity and asset compensation [8][12] - Continuous strengthening of internal controls and audit mechanisms to mitigate historical risks and enhance compliance [8][13] - The company is actively pursuing legal measures to recover debts and ensure the execution quality of debt resolution plans [9][11] Group 4: Innovation and Product Development - The company emphasizes the integration of raw materials, formulations, medical devices, and health products to create a comprehensive pharmaceutical ecosystem [6] - It aims to enhance product lifecycle and maintain competitive advantages in the chemical drug sector through consistent evaluation and innovation [6] - The company has obtained a total of 545 authorized patents, reflecting its commitment to innovation [3]

证券代码：300110 证券简称：华仁药业 公告编号：2025-032 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"一次性滑移垫"的《医疗器械注 册证》，现将相关情况公告如下： 8、注册分类：Ⅱ类 9、批准日期：2025 年 4 月 23 日 10、有效期至：2030 年 4 月 22 日 一、医疗器械基本情况 1、注册人名称：青岛华仁医疗用品有限公司 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号无菌医疗器械车间楼 4、产品名称：一次性滑移垫 5、型号、规格：I 型、Ⅱ型、Ш 型、Ⅳ型、V 型、Ⅵ型 6、适用范围：用于医疗机构运送、移动患者用 7、注册证编号：鲁械注准 20252150222 二〇二五年五月六日 二、医疗器械相关情况 公司本次获得二类医疗器械注册证的一次性滑移垫用于医疗机构运送、移动 患者用，产品包含 6 个型号规格 ...

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

证券代码：300110 证券简称：华仁药业 公告编号：2025-031 华仁药业股份有限公司 红塔创新于本次减持计划期间累计减持公司股份 11,819,960 股，该股份来源 于公司首次公开发行股票前其持有的股份，均已解除限售。减持股份具体情况如 下： | 股东 | 股份 | 减持 | 减持期间 | 减持均价 | 减持股数 | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 性质 | 方式 | | （元） | (股） | （%） | | 红塔创 | 无限售 条件股 | 集中竞 | 2025.4.14- | 3.00 | 11,819,960 | 1.00 | | 新 | | 价 | 2025.4.29 | | | | | | 份 | | | | | | 二、红塔创新本次减持前后持股情况 | | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 股东 | 股份 | | | | | | 名称 | 性质 | 股数（股） | 占总股本 | 股数（股） | 占总股 ...

Core Viewpoint - Huaren Pharmaceutical (300110) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has received the "Medical Device Registration Certificate" for "Medical Wound Dressings" from the Shandong Provincial Drug Administration, which will enhance the company's product line and competitiveness in the medical device sector [1] Group 1 - The newly approved product is suitable for non-chronic wounds and surrounding skin care, comprising 15 different specifications [1] - There are currently 22 companies in the domestic market with similar listed products, indicating a competitive landscape [1] - The acquisition of this registration certificate will support the synergistic development of the company's segments, including raw materials, formulations, medical devices, and medical packaging [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-029 华仁药业股份有限公司 关于参加 2025 年青岛辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华仁药业股份有限公司（以下简称"公司"） 将参加由青岛证监局指导、青岛市上市公司协会与深圳市全景网络有限公司联合 举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现将相关事项公 告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。届 时公司董事长张力先生、总裁李健先生、独立董事刘勇先生、财务总监韩莉萍女 士及董事会秘书冯新光先生将以在线交流形式就公司治理、发展战略、经营状况 和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大投资者踊 跃参与! 特此公告。 华仁药业股份有限公司董事会 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-030 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"医用创面敷料"的《医疗器械注 册证》，现将相关情况公告如下： 一、医疗器械基本情况 1、注册人名称：青岛华仁医疗用品有限公司 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号 2 号楼、无菌医疗器械车间楼 4、产品名称：医用创面敷料 5、产品型号、规格：型号：圆型、方型、椭圆型；规格：10g/片、15g/片、 20g/片、25g/片、30g/片 6、适用范围：适用于非慢性创面（如浅表性创面、激光/光子/果酸换肤后的 创面）及周围皮肤的护理 7、注册证编号：鲁械注准 20252140226 8、注册分类：Ⅱ类 9、批准日期：2025 年 4 月 23 日 10、有效期至：2030 年 4 月 22 日 二、医疗器械相关情况 ...

关于副总裁、董事会秘书辞职及聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、副总裁、董事会秘书辞职情况 华仁药业股份有限公司（以下简称"公司"）董事会于近日收到公司副总裁、董 事会秘书孟祥园女士的辞职报告，孟祥园女士因个人原因申请辞去公司副总裁、董 事会秘书职务，辞职后仍在公司担任其他职务。根据《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定，孟 祥园女士的辞职报告自送达董事会之日起生效。 证券代码：300110 证券简称：华仁药业 公告编号：2025-027 华仁药业股份有限公司 二、聘任董事会秘书情况 公司于 2025 年 4 月 29 日召开第八届董事会第八次（临时）会议，审议通过了 《关于聘任董事会秘书的议案》。经公司董事会提名委员会审核通过，公司董事会 同意聘任公司副总裁冯新光先生为公司董事会秘书，任期自本次董事会审议通过之 日起至第八届董事会任期届满之日止。 冯新光先生已取得深圳证券交易所认可的董事会秘书资格证书，熟悉履职相关 的法律法规，具备与岗位要求相适应的职业操守， ...